At week 2, 2/5 mice from the CD276 group and 2/5 from the Dual group showed a significantly smaller tumor burden, compared to the controls (Fig. 13B), visible also in the delayed tumor volume growth (Fig. 13C), and stagnation of bioluminescence signal (Fig. 13D). This evidence concerns the gene CD276 and neoplasm.